CTLA4 and urinary bladder neoplasm: Here, we provide direct evidence that PD-1 is a primary suppressive pathway utilized by bladder tumour cells to ‘escape' α-CTLA-4 monotherapy by showing that α-CTLA-4 therapy upregulates PD-1/PD-L1 expression and that bladder tumour cells express high levels of PD-L1.